Integra Lifesciences Showcases Gene-Writing Innovations at ASGCT 2025 Meeting
- Integra Therapeutics will present groundbreaking pre-clinical data on gene-writing technology at ASGCT 2025 in New Orleans.
- The company’s CAR-T cells show enhanced efficacy in treating B-ALL tumors and autoimmune diseases through innovative production processes.
- Integra's collaboration on the FiCAT platform aims to improve gene editing efficiency beyond traditional CRISPR-Cas9 methods.
Integra Therapeutics Set to Showcase Breakthroughs in Gene-Writing Technology at ASGCT 2025
Integra Therapeutics, a frontrunner in the field of gene-writing technology, prepares to unveil promising new pre-clinical data at the upcoming 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in New Orleans, scheduled for May 13 to 17, 2025. Dr. Avencia Sánchez-Mejías, the company’s CEO and Co-Founder, underscores the importance of this presentation, which highlights the capabilities of their cutting-edge gene-writing platform. This innovative technology boasts double-digit editing efficiencies and the potential for multi-gene integration, particularly enhancing the development of cell therapies targeting oncological and autoimmune diseases.
One of the key advancements presented involves the creation of CAR-T cells that can express complex chimeric antigen receptors (CARs), including bispecific versions equipped with a kill switch. By simplifying production processes, these CAR-T cells demonstrate superior efficacy compared to existing methodologies, particularly in eliminating B-ALL tumor cells and addressing autoimmune conditions such as lupus and rheumatoid arthritis. The novel approach allows for a more effective therapeutic strategy, addressing some of the pressing challenges in the field of oncology and immunology.
Integra’s presentation will also delve into specific innovations achieved through the use of CRISPR-Cas12l nucleases combined with their proprietary FiCAT platform, developed in collaboration with Caszyme. This strategic partnership aims to enhance the efficiency of gene editing beyond what traditional CRISPR-Cas9 methodologies can offer. Among the topics slated for discussion are the “Precise Gene Writing System for CAR-T cell therapy generation” and the establishment of a “viral-free FiCAT gene writing platform for liver-directed in vivo applications.” The FiCAT platform specifically addresses critical challenges in gene-editing technologies for ex vivo therapies, offering a flexible and efficient solution for safe editing, even for large genes in primary cells.
In addition to showcasing its advancements in CAR-T cell therapies, Integra Therapeutics positions itself as a significant player in the evolving gene-editing landscape. The upcoming ASGCT meeting represents an opportunity for the company to highlight its innovative strategies and collaborative efforts, potentially attracting further interest in its technologies and applications for both oncology and autoimmune disease treatments.
As the field of gene and cell therapy continues to progress rapidly, Integra’s commitment to developing safe and efficient gene-editing solutions places it at the forefront of transformative healthcare advancements. The results shared at ASGCT 2025 are expected to not only enhance the company’s visibility but also contribute meaningfully to the broader discourse on gene therapy innovations.